Management of imatinib-resistant patients with chronic myeloid leukemia

Therapeutic Advances in Hematology

Volumn 4, Issue 2, 2013, Pages 103-117

  Bhamidipati, Pavan Kumar ^a   Kantarjian, Hagop ^a   Cortes, Jorge ^a   Cornelison, A Megan ^a   Jabbour, Elias ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

CML; imatinib resistance; treatment; tyrosine kinase inhibitor

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; DASATINIB; HOMOHARRINGTONINE; IMATINIB; INTERFERON; LIVER ENZYME; MULTIDRUG RESISTANCE PROTEIN; NILOTINIB; PANCREAS ENZYME; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRIACYLGLYCEROL LIPASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ARTHRALGIA; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; FATIGUE; GENE AMPLIFICATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; METAPHASE; MUSCLE CRAMP; MUSCLE SPASM; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; NONHUMAN; PANCREATITIS; PATIENT COMPLIANCE; PLEURA EFFUSION; POINT MUTATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

EID: 84993699130     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620712468289     Document Type: Review

References (79)

1. Alvarado Y. Kantarjian H. O'Brien S. Faderl S. Borthakur G. Burger J. et al. (2009) Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115: 3709–3718.
2. Baccarani M. Cortes J. Pane F. Niederwieser D. Saglio G. Apperley J. et al. (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27: 6041–6051.
3. Baccarani M. Dreyling M. (2009) Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl. 4): 105–107.
4. Baccarani M. Saglio G. Goldman J. Hochhaus A. Simonsson B. Appelbaum F. et al. (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108: 1809–1820.
5. Bixby D. Talpaz M. (2009) Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program 461–476.
6. Branford S. Melo J. Hughes T. (2009) Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114: 5426–5435.
7. Branford S. Rudzki Z. Walsh S. Parkinson I. Grigg A. Szer J. et al. (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102: 276–283.
8. Brave M. Goodman V. Kaminskas E. Farrell A. Timmer W. Pope S. et al. (2008) Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14: 352–359.
9. Che X. Nakajima Y. Sumizawa T. Ikeda R. Ren X. Zheng C. et al. (2002) Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519. Cancer Lett 187: 111–119.
10. Chu E. de Vita V. (2010.) Cancer Chemotherapy Drug Manual. Sudbury, MA: Jones and Bartlett Publishers.
11. Cortes J. Kantarijian H. Shah N. Bixby D. Mauro M. Flinn I. et al. (2011) Subset analysis of response to treatment of chronic phase CML in a phase 1 study of ponatinib in refractory hematologic malignancies. Blood 118: abstract 602.
12. Cortes J. Talpaz M. Bixby D. Deininger M. Shah N. Flinn I. et al. (2010 a) A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies emerging safety and clinical response findings. ASH Annual Meeting Abstracts 116: 210.
13. Cortes J. Wetzler M. Lipton J. Nicolini F. Baccarani M. Baer M. et al. (2010 b) Subcutaneous omacetaxine (OM) treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients following multiple tyrosine kinase inhibitor (TKI) failure. ASH Annual Meeting Abstracts 116: 2290.
14. Cortes-Franco J. Khoury H. Nicolini F. Corm S. Lipton J. Jones D. et al. (2009) Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr-Abl T315I mutation – results of an ongoing multicenter phase 2 / 3 study. ASH Annual Meeting Abstracts 114: 644.
15. Darkow T. Henk H. Thomas S. Feng W. Baladi J. Goldberg G. et al. (2007) Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmaco Economics 25: 481–496.
16. Deininger M. (2008) Nilotinib. Clinical Cancer Res 14: 4027–4031.
17. Deininger M. Buchdunger E. Druker B. (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640–2653.
18. Deininger M. Goldman J. Lydon N. Melo J. (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90: 3691–3698.
19. Deininger M. O'Brien S. Guilhot F. Goldman J. Hochhaus A. Hughes T. et al. (2009) International randomized study of interferon vs STI 571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 114: 462.
20. Druker B. Guilhot F. O’ Brien S. Gathmann I. Kantarjian H. Gattermann N. et al.; IRIS Investigators (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408–2417.
21. Druker B. Lydon N. (2000) Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3–7.
22. Gambacorti-Passerini C. Barni R. Le Coutre P. Zucchetti M. Cabrita G. Cleris L. et al. (2000) Role of alpha 1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92: 1641–1650.
23. Gambacorti-Passerini C. Kim D. Kantarjian H. Brummendorf T. Dyagil I. Griskevicius L. et al. (2010) An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. Blood 116.
24. Gorre M. Mohammed M. Ellwood K. Hsu N. Paquette R. Rao P. et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876–880.
25. Hochhaus A. Baccarani M. Deininger M. Apperley J. Lipton J. Goldberg S. et al. (2008 a) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22: 1200–1206.
26. Hochhaus A. Druker B. Sawyers C. Guilhot F. Schiffer C. Cortes J. et al. (2008 b) Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 111: 1039–1043.
27. Hochhaus A. Giles F. Apperely J. Ossenkoppele G. Wang J. Gallagher N. et al. (2009 a) Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study;. Haematologica 94(Suppl. 2): 256.
28. Hochhaus A. Kreil S. Corbin A. La Rosee P. Muller M. Lahaye T. et al. (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16: 2190–2196.
29. Hochhaus A. O'Brien S. Guilhot F. Druker B. Branford S. Foroni L. et al. (2009 b) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23: 1054–1061.
30. Hughes T. Deininger M. Hochhaus A. Branford S. Radich J. Kaeda J. et al. (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108: 28–37.
31. Hughes T. Hochhaus A. Branford S. Muller M. Kaeda J. Foroni L. et al. (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI 571 (IRIS). Blood 116: 3758–3765.
32. Hughes T. Kaeda J. Branford S. Rudzki Z. Hochhaus A. Hensley M. et al. (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349: 1423–1432.
33. Jabbour E. Deininger M. Hochhaus A. (2011 a) Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 25: 201–210.
34. Jabbour E. Kantarjian H. Abruzzo L. O'Brien S. Garcia-Manero G. Verstovsek S. et al. (2007) Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110: 2991–2995.
35. Jabbour E. Kantarjian H. Cortes J. (2011 b) Chronic myeloid leukemia. Emerg Cancer Ther 2: 239–258.
36. Jabbour E. Kantarjian H. Jones D. Shan J. O'Brien S. Reddy N. et al. (2009 a) Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113: 2154–2160.
37. Jabbour E. Kantarjian H. Jones D. Talpaz M. Bekele N. O'Brien S. et al. (2006) Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20: 1767–1773.
38. Jabbour E. Kantarjian H. O'Brien S. Shan J. Garcia-Manero G. Wierda W. et al. (2009 b) Predictive factors for response and outcome in patients (pts) treated with second generation tyrosine kinase inhibitors (2-TKI) for chronic myeloid leukemia in chronic phase (CML-CP) post imatinib failure. Blood 114: 210.
39. Kantarjian H. Giles F. Bhalla K.N. et al. (2010) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results [published online ahead of print November 22, 2010]. Blood. DOI: 10.1182/blood-2010-03-277152.
40. Kantarjian H. Giles F. Wunderle L. Bhalla K. O'Brien S. Wassmann B. et al. (2006 a) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542–2551.
41. Kantarjian H. Hochhaus A. Saglio G. Souza C. Flinn I. Stenke L. et al. (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12: 841–851.
42. Kantarjian H. Larson R. Guilhot F. O'Brien S. Mone M. Rudoltz M. et al. (2009 a) Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 115: 551–560.
43. Kantarjian H. Pasquini R. Levy V. Jootar S. Holowiecki J. Hamerschlak N. et al. (2009 b) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 115: 4136–4147.
44. Kantarjian H. Shan J. Jones D. O'Brien S. Rios M. Jabbour E. et al. (2009 c) Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol 27: 3659–3663.
45. Kantarjian H. Talpaz M. O'Brien S. Jones D. Giles F. Garcia-Manero G. et al. (2006 b) Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 108: 1835–1840.
46. Khorashad J. de Lavallade H. Apperley J. Milojkovic D. Reid A. Bua M. et al. (2008) Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 26: 4806–4813.
47. Kotaki M. Motoji T. Takanashi M. Wang Y. Mizoguchi H. (2003) Anti-proliferative effect of the abl tyrosine kinase inhibitor STI 571 on the P-glycoprotein positive K562/ADM cell line. Cancer letters 199: 61–68.
48. Le Coutre P. Tassi E. Varella-Garcia M. Barni R. Mologni L. Cabrita G. et al. (2000) Induction of resistance to the Abelson inhibitor STI 571 in human leukemic cells through gene amplification. Blood 95: 1758–1766.
49. Lee F. Fandi A. Voi M. (2008) Overcoming kinase resistance in chronic myeloid leukemia. Int J Biochem Cell Biol 40: 334–343.
50. Loriaux M. Deininger M. (2004) Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma 45: 2197–2203.
51. Lucas C. Wang L. Austin G. Knight K. Watmough S. Shwe K. et al. (2008) A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 22: 1963–1966.
52. Mahon F. Deininger M. Schultheis B. Chabrol J. Reiffers J. Goldman J. et al. (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96: 1070–1079.
53. Marin D. Bazeos A. Mahon F. Eliasson L. Milojkovic D. Bua M. et al. (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28: 2381–2388.
54. Marin D. Milojkovic D. Olavarria E. Khorashad J. de Lavallade H. Reid A. et al. (2008) European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112: 4437–4444.
55. Mauro M. Baccarani M. Cervantes F. Lipton H. Matloub R. Sihna R. et al. (2009) Dasatinib 2-year efficacy in patients with chronic-phase chronic myeloid leukemia with resistance or intolerance to imatinib (START-C). J Clin Oncol 26: abstract 7009.
56. Ng K. Hillmer A. Chuah C. Juan W. Ko T. Teo A. et al. (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 18: 521–528.
57. Nicolini F. Corm S. Le Q. Sorel N. Hayette S. Bories D. et al. (2006) Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 20: 1061–1066.
58. Noens L. van Lierde M. de Bock R. Verhoef G. Zachee P. Berneman Z. et al. (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113: 5401–5411.
59. O'Brien S. Guilhot F. Larson R. Gathmann I. Baccarani M. Cervantes F. et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994–1004.
60. O'Brien S.B.E. Abboud C.N. Akhtari M. Altman J. Berman E. de Angelo D.J. et al. NCCN Chronic Myelogenous Leukemia Panel and (Internet), M.N.C.C.n. (2011) NCCN clinical practice guidelines in oncology: chronic myeloid leukemia. Available from: http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf (accessed on 11 September 2012).
61. O'Hare T. Shakespeare W. Zhu X. Eide C. Rivera V. Wang F. et al. (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer cell 16: 401–412.
62. O'Hare T. Walters D. Stoffregen E. Jia T. Manley P. Mestan J. et al. (2005) In vitro activity of Bcr-Abl inhibitors AMN 107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65: 4500–4505.
63. Perez-Galan P. Roue G. Villamor N. Campo E. Colomer D. (2007) The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109: 4441–4449.
64. Pinilla-Ibarz J. Cortes J. Mauro M. (2011) Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications. Cancer 117: 688–697.
65. Quintas-Cardama A. Kantarjian H. O'Brien S. Borthakur G. Bruzzi J. Munden R. et al. (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25: 3908–3914.
66. Ravandi F. (2011) Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk 11: 198–203.
67. Ross D. Branford S. Moore S. Hughes T. (2006) Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia 20: 664–670.
68. Rumpold H. Wolf A. Gruenewald K. Gastl G. Gunsilius E. Wolf D. (2005) RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol 33: 767–775.
69. Shah N. (2005) Loss of response to imatinib: mechanisms and management. Hematology Am Soc Cancer Educ Program 183–187.
70. Shah N. (2007) Medical management of CML. Hematology Am Soc Cancer Educ Program 371–375.
71. Soverini S. Colarossi S. Gnani A. Rosti G. Castagnetti F. Poerio A. et al. (2006) Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12: 7374–7379.
72. Soverini S. Gnani A. de Benedittis C. Castagnetti F. Gugliotta G. Bochicchio M. et al. (2011) Validation of the new European LeukemiaNet (ELN) recommendations for Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia: an analysis of the GIMEMA CML Working Party Studies. Blood 118: abstract 112.
73. Tam C. Kantarjian H. Garcia-Manero G. Borthakur G. O'Brien S. Ravandi F. et al. (2008) Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112: 516–518.
74. Thomas J. Wang L. Clark R. Pirmohamed M. (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104: 3739–3745.
75. Wang L. Giannoudis A. Lane S. Williamson P. Pirmohamed M. Clark R. (2008) Expression of the uptake drug transporter hOCT 1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83: 258–264.
76. Weisberg E. Griffin J. (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI 571 in BCR/ABL-transformed hematopoietic cell lines. Blood 95: 3498–3505.
77. White D. Saunders V. Dang P. Engler J. Zannettino A. Cambareri A. et al. (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108: 697–704.
78. Widmer N. Decosterd L. Csajka C. Leyvraz S. Duchosal M. Rosselet A. et al. (2006) Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol 62: 97–112.
79. Zhang W. Cortes J. Yao H. Zhang L. Reddy N. Jabbour E. et al. (2009) Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 27: 3642–3649.